Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual ...

A biorepository centre was inaugurated at the Department of Pathology in JSS Hospital in Mysuru on Wednesday.

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in ...

The data shows a significant reduction in mutant huntingtin protein in the cerebrospinal fluid of treated patients.